The Phase II TRIG-05 trial is assessing TI-001, an investigational, nasally-delivered oxytocin therapeutic currently being examined to determine its efficacy, tolerability, and safety in chronic migraine patients. Secondary
As part of the agreement, PBL will use its ligand design and screening capabilities to identify Mimetic affinity ligands with the ability to capture and purify the new
Beleodaq (belinostat) for Injection, a novel pan-HDAC inhibitor is intended for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). The FDA establishes review
The company is likely to conduct the Phase II study for CF102 in Israel, Europe and the US. This study is designed to assess the safety and efficacy
The randomized, open-label, multicenter Phase II trial is being carried out in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT). It is being conducted in six US cancer
Under the deal, Kinex will receive an upfront payment, milestones and royalties, while PharmaEssentia has committed to carryout clinical studies in Taiwan to contribute to the global registration
DavosPharma is expected to complete the manufacturing of the drug in the second quarter of 2014 and is also in the process of preparing its investigational new drug
XLMTM is a rare, inherited disorder characterized by severe muscle weakness and respiratory impairment. The company said that AT001 is a novel drug candidate based on adeno-associated virus
The new facility will offer manufacturing capacity for emerging compounds within the company’s oncology and immunology pipeline to serve markets globally. Scheduled to be operational by 2019, the
Under the deal, the company will have sole rights to develop and market the technology across the world. The company said that protecting the fundamental enabling technology establishes
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.